Is Flexeril Nephrotoxic?
No, Flexeril (cyclobenzaprine) is not nephrotoxic. Cyclobenzaprine does not cause direct kidney injury or dysfunction and is not listed among medications that affect renal function through hemodynamic or structural mechanisms.
Evidence from Drug Labeling and Guidelines
The FDA drug label for cyclobenzaprine 1 provides comprehensive pharmacokinetic data showing that the drug is extensively metabolized in the liver and excreted primarily as glucuronides via the kidney. Critically, there is no mention of nephrotoxicity in the adverse effects profile, contraindications, or warnings sections of the official labeling.
The pharmacokinetic profile demonstrates:
- Metabolism occurs via hepatic cytochrome P450 enzymes (3A4, 1A2, and 2D6)
- Elimination half-life of 32 hours (range 8-37 hours)
- Renal excretion is of metabolites, not active drug causing tubular damage
Contraindications Related to Renal Function
While cyclobenzaprine is contraindicated in patients with significant renal dysfunction 2, this is not due to nephrotoxicity. The contraindication exists because:
- Impaired renal elimination can lead to drug and metabolite accumulation
- This increases risk of systemic adverse effects (sedation, anticholinergic effects, hypotension)
- The concern is about drug accumulation causing toxicity to other organs, not kidney damage
Comparison with Truly Nephrotoxic Agents
Recent KDIGO guidelines 3 provide comprehensive frameworks for classifying nephrotoxic drugs through two main mechanisms:
- Hemodynamic effects (systemic hypotension, altered glomerular perfusion)
- Structural damage (tubular injury, glomerular damage, obstruction)
Cyclobenzaprine does not appear in any nephrotoxicity classification systems or lists of drugs requiring renal monitoring for kidney injury. In contrast, truly nephrotoxic agents like aminoglycosides (streptomycin, amikacin, kanamycin) cause documented nephrotoxicity requiring dose adjustment and monitoring 4.
Clinical Implications
In patients with normal renal function: Cyclobenzaprine can be used without concern for causing kidney damage.
In patients with existing renal impairment:
- Avoid use due to risk of drug accumulation and systemic toxicity
- If absolutely necessary, use with extreme caution and close monitoring for CNS and cardiovascular effects
- The perioperative guideline recommends holding on day of operation 2
Common Pitfalls to Avoid
Do not confuse "contraindicated in renal dysfunction" with "nephrotoxic." Many drugs are contraindicated in kidney disease because they accumulate and cause harm to other organ systems, not because they damage the kidneys themselves. Cyclobenzaprine falls into this category—it requires renal dose adjustment or avoidance to prevent systemic toxicity (sedation, anticholinergic crisis, cardiovascular effects), not to protect the kidneys from direct injury.
The extensive overdose literature 5, 6, 7, 8 documents anticholinergic effects, CNS depression, and cardiovascular effects, but no cases of acute kidney injury from cyclobenzaprine toxicity, further supporting its lack of nephrotoxic potential.